BioSpace News Archive

Drug Development

European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (“low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).

January 14, 2019
·
35 min read
Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX:NVCN) announced today that it has received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market.

January 14, 2019
·
9 min read
FDA

FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination

First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the first vaccination to help protect against tetanus, diphtheria and pertussis, offering flexibility for health care providers to help manage their immunization schedules(2)

January 14, 2019
·
7 min read
Drug Development

Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer

Data will be presented at ASCO 2019 Gastrointestinal Cancers Symposium

January 14, 2019
·
19 min read
Drug Development

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial

January 14, 2019
·
15 min read
Drug Development

Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Results from Phase 3 KEYNOTE-181 Trial to be Presented at 2019 Gastrointestinal Cancers Symposium (ASCO GI)

January 14, 2019
·
31 min read
Business

Gravie Hires Charles Marentette as Chief Financial Officer to Support Company’s Rapid Growth

Gravie, a company that’s been reinventing health benefits since 2013, announced that Charles Marentette has joined the team as Chief Financial Officer.

January 14, 2019
·
2 min read
Drug Development

Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody

Innovent Biologics, Inc. announced that the first patient has been successfully dosed in a phase I clinical trial of anti-CD47 monoclonal antibody (IBI188) for patients with advanced malignancies.

January 14, 2019
·
4 min read
Drug Development

Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium

Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric and Gastric Esophageal Junction (GEJ) Cance

January 14, 2019
·
4 min read
Job Trends

Cage Free Care redefines coverage through Direct Primary Care

Healthcare has never been easy. We all need it, but picking and choosing what plans to go with, the right doctor to see and making sure the selected facility is in network can be overwhelming.

January 14, 2019
·
1 min read